TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix Limited has received a significant development milestone payment of ¥400 million (~AU$4.2 million) from FUSO Pharmaceutical Industries Ltd., marking a key step in their collaboration for the commercialization of DMX-200 in Japan. This milestone supports the recruitment for the ACTION3 clinical trial in Japan, potentially leading to further payments and royalties. The agreement with FUSO is part of Dimerix’s broader strategy to partner with multiple regional entities, potentially yielding up to ~AU$1.4 billion in upfront and milestone payments, as well as royalties, strengthening its market position and operational capabilities.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, particularly kidney diseases. The company is advancing its proprietary Phase 3 product candidate, DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) and DMX-700 for respiratory disease. Dimerix utilizes its Receptor Heteromer Investigation Technology (Receptor-HIT) platform to identify new drug opportunities.
Average Trading Volume: 3,349,531
Technical Sentiment Signal: Buy
Current Market Cap: A$341.2M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.